Neoadjuvant Nivolumab Plus Ipilimumab Shows Trend Towards Long-Term Clinical Benefit versus Chemotherapy in Patients with Resectable NSCLC By Ogkologos - February 24, 2025 19 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 816 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab to Unresectable or Advanced HCC ESMO Sarcoma and Rare Cancers Congress 2025, Lugano, Switzerland, 20-22 March New on NCI’s Websites for March 2025 MOST POPULAR Drug Combination Shows Promise for Rhabdomyosarcoma, but Can It Get to... December 9, 2022 Marginal Benefit in Overall and Progression-Free Survival from New Anticancer Drugs August 12, 2022 Sharing Energy April 14, 2021 Educators Raise Money in Memory of Teacher Who Dedicated Herself to... January 19, 2021 Load more HOT NEWS New Research in Treating Lymphoma and Improving Equity in Cancer Clinical... What Caregivers Should Know About End-of-Life Care Issues for People With... 10 Ways to Brave Cancer Treatment: Tips from a Survivor What to Know About the Different Types of Mastectomies for Breast...
